Additionally, MET amplification is recognized as an off-target resistance mechanism in ALK+ NSCLC, with crizotinib demonstrating potential activity owing to its dual anti-ALK and anti-MET effects. The gene discussed is MET; the disease is non-small cell lung carcinoma.